Roche's Xofluza reduces influenza transmission in phase III trial

SOUTH SAN FRANCISCO (dpa-AFX) – Roche’s (RHHBY) Xofluza (baloxavir marboxil), an antiviral drug, met its primary endpoint in the Phase III CENTERSTONE trial. Results showed that a single oral dose of Xofluza significantly reduced the risk of influenza transmission to others in a household. In addition, Xofluza was well tolerated, with no new safety concerns reported.

The company noted that CENTERSTONE is the first global Phase III study to demonstrate a transmission reduction benefit with an antiviral agent used to treat a viral respiratory illness. These new data may contribute to the benefits of Xofluza, which is currently approved to treat symptoms and prevent infection after exposure to the virus.

Visit rttnews.com for more health news.

Related Posts

EyePoint Pharmaceuticals Reports Incentive Grants Under NASDAQ Listing Rule 5635(c)(4)

House of Sweets available for free Loading on Bahnhofstraße with long opening hours

France in pictures